[
1. Otani IM, Banerji A. Acquired C1 Inhibitor Deficiency. Immunol Allergy Clin North Am. 2017;37:497-511. DOI: 10.1016/j.iac.2017.03.00210.1016/j.iac.2017.03.002
]Search in Google Scholar
[
2. Zanichelli A, Azin GM, Wu MA, Suffritti C, Maggioni L, Caccia S, et al. Diagnosis, Course, and Management of Angioedema in Patients With Acquired C1-Inhibitor Deficiency. J Allergy Clin Immunol Pract. 2017;5:1307-13. DOI: 10.1016/j.jaip.2016.12.03210.1016/j.jaip.2016.12.032
]Search in Google Scholar
[
3. Wu MA, Castelli R. The Janus faces of acquired angioedema: C1-inhibitor deficiency, lym-phoproliferation and autoimmunity. Clin Chem Lab Med. 2016;54:207-14. DOI: 10.1515/cclm-2015-019510.1515/cclm-2015-0195
]Search in Google Scholar
[
4. Pólai Z, Balla Z, Andrási N, Kőhalmi KV, Temesszentandrási G, Benedek S, et al. A follow-up survey of patients with acquired angioedema due to C1-inhibitor deficiency. J Intern Med. 2021;289:547-58. DOI: 10.1111/joim.1318210.1111/joim.13182
]Search in Google Scholar
[
5. Schreiber AD, Zweiman B, Atkins P, Goldwein F, Pietra G, Atkinson B, et al. Acquired angi-oedema with lymphoproliferative disorder: association of C1 inhibitor deficiency with cellular abnormality. Blood. 1976;48:567-80. DOI: 10.1182/blood.V48.4.567.56710.1182/blood.V48.4.567.567
]Search in Google Scholar
[
6. Frémeaux-Bacchi V, Guinnepain MT, Cacoub P, Dragon-Durey MA, Mouthon L, Blouin J, et al. Prevalence of monoclonal gammopathy in patients presenting with acquired angioedema type 2. Am J Med. 2002;113:194-9. DOI: 10.1016/S0002-9343(02)01124-510.1016/S0002-9343(02)01124-5
]Search in Google Scholar
[
7. Bork K, Staubach-Renz P, Hardt J. Angioedema due to acquired C1-inhibitor deficiency: spec-trum and treatment with C1-inhibitor concentrate. Orphanet J Rare Dis. 2019;14:65. DOI: 10.1186/s13023-019-1043-310.1186/s13023-019-1043-3
]Search in Google Scholar
[
8. Gajra A, Vajpayee N, Grethlein SJ. Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma. Am J Hematol. 2004;77:196-7. DOI: 10.1002/ajh.2016910.1002/ajh.20169
]Search in Google Scholar
[
9. Takagi K, Yoshida A, Iwasaki H, Inoue H, Ueda T. Anti-CD20 antibody (Rituximab) therapy in a myasthenia gravis patient with follicular lymphoma. Ann Hematol. 2005;84:548-50. DOI: 10.1007/s00277-005-1050-410.1007/s00277-005-1050-4
]Search in Google Scholar
[
10. Rezania K, Soliven B, Baron J, Lin H, Penumalli V, van Besien K. Myasthenia gravis, an auto-immune manifestation of lymphoma and lymphoproliferative disorders: case reports and review of literature. Leuk Lymphoma. 2012;53:371-80. DOI: 10.3109/10428194.2011.61542610.3109/10428194.2011.615426
]Search in Google Scholar
